Flaxseed-rich diet blocks prostate cancer growth and development in mice

November 11, 2002

Durham, N.C. -- A diet rich in flaxseed seems to reduce the size, aggressiveness and severity of tumors in mice that have been genetically engineered to develop prostate cancer, according to new research from Duke University Medical Center. And in 3 percent of the mice the flaxseed diet kept them from getting the disease at all..

"We are cautiously optimistic about these findings," said Wendy Demark-Wahnefried, Ph.D., associate professor, division of urology and senior author of the study that appears in the November 2002 issue of the journal Urology. "The amount of flaxseed given to each mouse was 5 percent of its total food intake, which would be a very difficult amount for humans to eat, but it does signal that we are on the right track and need to continue research in this area."

According to Demark-Wahnefried, planned clinical trials must be completed before it can be concluded that dietary flaxseed is a useful protective against prostate cancer in humans.

The research was sponsored by the National Institute of Aging, the National Cancer Institute and the Committee for Urologic Research Education and Development at Duke University Medical Center.

Clinical studies by other researchers have suggested that dietary fiber reduces cancer risk, and omega-3 fatty acids also have shown a protective benefit against cancer. Flaxseed is the richest plant source of omega-3 fatty acids and is high in fiber. Also, flaxseed is a source of lignan, a specific family of fiber-related compounds that appear to play a role in influencing both estrogen and testosterone metabolism. Since testosterone may be important in the progression of prostate cancer, lignan could help inhibit the growth and development of the disease.

In the Duke study, 135 mice genetically engineered to develop prostate cancer were divided into a control group and an experimental group. The experimental group received a regular mouse diet, but 5 percent of the diet was in the form of flaxseed. Half of the mice in both groups were fed their respective diets for 20 weeks and the remainder for 30 weeks. At the 20- and 30-week end points, the mice were autopsied to check for tumor growth and progression of the disease to other organs.

"Tumors in the untreated control group were twice the size of tumors in the flaxseed group," said Xu Lin, M.D., research associate, division of urology and lead author of the study. "The tumors were also less aggressive in the flaxseed group, and two of the mice in the flaxseed group did not develop prostate cancer at all. The rates of apoptosis (tumor cell death) were also higher in the flaxseed group. And while it was not statistically significant, the flaxseed group had fewer rates of the cancer spreading to other organs. "

While the results are promising, the researchers say they are not surprising. The study is the third in a series by the Duke Medical Center researchers to show the benefits of flaxseed in reducing the growth and development of prostate cancer.

The first study, published in July 2001 in Urology, demonstrated that a low-fat diet supplemented with flaxseed was associated with slower tumor growth. In this pilot study, 25 men with prostate cancer began adding ground flaxseed to their diets for 34 days. At the end of the study, the men saw a drop in testosterone levels and a trend toward lower prostate specific antigen (PSA) levels, a marker for prostate cancer. The diet also was tolerated well and gave the authors hope for this dietary intervention.

The second study, published in the November-December 2001 issue of Anticancer Research, examined the effect lignans have on prostate cancer cell lines. This study showed that flaxseed-derived lignans inhibited the growth of three distinct human prostate cancer cell lines through hormonally dependent and independent mechanisms.

"So far we have observed the suppression of prostate cancer in humans, mice and at the cellular level," said Lin. "It's not a fluke or a coincidence. It's an encouraging line of research."

Demark-Wahnefried adds, "Our results are encouraging. However, before we can truly state that flaxseed is beneficial in humans, larger well-controlled trials are needed. The National Cancer Institute has provided us with the support to conduct a randomized clinical trial in 160 men with prostate cancer that will examine whether a low-fat diet, flaxseed supplementation or a combination of low-fat diet and flaxseed supplementation will be most effective in stopping prostate cancer cells from dividing. That trial is currently under way."
-end-


Duke University Medical Center

Related Prostate Cancer Articles from Brightsurf:

Low risk of cancer spread on active surveillance for early prostate cancer
Men undergoing active surveillance for prostate cancer have very low rates - one percent or less - of cancer spread (metastases) or death from prostate cancer, according to a recent study published in the Journal of Urology®, an Official Journal of the American Urological Association (AUA).

ESMO 2020: Breast cancer drug set to transform prostate cancer treatment
A drug used to treat breast and ovarian cancer can extend the lives of some men with prostate cancer and should become a new standard treatment for the disease, concludes a major trial which is set to change clinical practice.

Major trial shows breast cancer drug can hit prostate cancer Achilles heel
A drug already licensed for the treatment of breast and ovarian cancers is more effective than targeted hormone therapy at keeping cancer in check in some men with advanced prostate cancer, a major clinical trial reports.

The Lancet: Prostate cancer study finds molecular imaging could transform management of patients with aggressive cancer
Results from a randomised controlled trial involving 300 prostate cancer patients find that a molecular imaging technique is more accurate than conventional medical imaging and recommends the scans be introduced into routine clinical practice.

Common genetic defect in prostate cancer inspires path to new anti-cancer drugs
Researchers found that, in prostate cancer, a mutation leading to the loss of one allele of a tumor suppressor gene known as PPP2R2A is enough to worsen a tumor caused by other mutations.

First prostate cancer therapy to target genes delays cancer progression
For the first time, prostate cancer has been treated based on the genetic makeup of the cancer, resulting in delayed disease progression, delayed time to pain progression, and potentially extending lives in patients with advanced, metastatic prostate cancer, reports a large phase 3 trial.

Men taking medications for enlarged prostate face delays in prostate cancer diagnosis
University of California San Diego School of Medicine researchers report that men treated with medications for benign prostatic hyperplasia (enlarged prostate) experienced a two-year delay in diagnosis of their prostate cancer and were twice as likely to have advanced disease upon diagnosis.

CNIO researchers confirm links between aggressive prostate cancer and hereditary breast cancer
The study has potential implications for families with members suffering from these types of tumours who are at an increased risk of developing cancer.

Distinguishing fatal prostate cancer from 'manageable' cancer now possible
Scientists at the University of York have found a way of distinguishing between fatal prostate cancer and manageable cancer, which could reduce unnecessary surgeries and radiotherapy.

Researchers find prostate cancer drug byproduct can fuel cancer cells
A genetic anomaly in certain men with prostate cancer may impact their response to common drugs used to treat the disease, according to new research at Cleveland Clinic.

Read More: Prostate Cancer News and Prostate Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.